Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections.

ABSTRACT: Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age ≤28 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chroma

SUBMITTER: Boer-Perez FS 

PROVIDER: S-EPMC12777573 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature